What type of study is this?

This is a Case Report study (also classified as: Meta-Analysis, Systematic Review).

What question did this study set out to answer?

To assess the impact of tocilizumab prophylaxis on CRS and other outcomes in patients receiving CAR-T cell immunotherapy for hematological malignancies.

December 8, 2025Blood

Tocilizumab prophylaxis in patients receiving CAR-T cell immunotherapy for hematological malignancies: A systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

MGMaria Gavriilaki PEPaschalis Evangelidis NENikolaos Evangelidis

Discussion

Member takes

Implication

Systematic review shows tocilizumab prophylaxis reduces cytokine release syndrome in patients with hematological malignancies receiving CAR-T therapy, suggesting improved outcomes.

Key Points

To assess the impact of tocilizumab prophylaxis on CRS and other outcomes in patients receiving CAR-T cell immunotherapy for hematological malignancies.
Conducted systematic review and meta-analysis of eligible studies
Included patients receiving CAR-T therapy and tocilizumab prophylaxis
Analyzed outcomes like incidence of CRS, progression-free survival, and adverse events
Prophylactic tocilizumab significantly reduced any grade CRS risk (RR=0.56)
Lower risk of clinically significant grade >2 CRS (RR=0.31)
58.3% experienced progression-free survival with prophylaxis
Adverse events and ICANS rates similar to published data.

Cite This Study

Gavriilaki et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e26b https://doi.org/10.1182/blood-2025-7668

View Full Paper

Ask AI

Bookmark

Implication

Systematic review shows tocilizumab prophylaxis reduces cytokine release syndrome in patients with hematological malignancies receiving CAR-T therapy, suggesting improved outcomes.

Tocilizumab prophylaxis in patients receiving CAR-T cell immunotherapy for hematological malignancies: A systematic review and meta-analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Tocilizumab prophylaxis in patients receiving CAR-T cell immunotherapy for hematological malignancies: A systematic review and meta-analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider